Skip to main content
Top
Published in: Journal of Gastroenterology 5/2010

01-05-2010 | Original Article—Liver, Pancreas, and Biliary Tract

Therapeutic factors considered according to the preoperative splenic volume for a prolonged increase in platelet count after partial splenic embolization for liver cirrhosis

Authors: Hiromitsu Hayashi, Toru Beppu, Kazutoshi Okabe, Toshiro Masuda, Hirohisa Okabe, Takatoshi Ishiko, Hideo Baba

Published in: Journal of Gastroenterology | Issue 5/2010

Login to get access

Abstract

Purpose

Infarcted splenic volume has been identified as the predictive factor for a prolonged increase in platelet count after partial splenic embolization (PSE). However, despite enough infarcted splenic volume, some patients show only a slight increase in platelet counts after PSE because of rapid regrowth of the noninfarcted splenic parenchyma within several months post-PSE. The purpose of this study was to determine the therapeutic factors based on the preoperative splenic volume for a prolonged increase in platelet counts after PSE.

Methods

In 72 cirrhotic patients with follow-ups longer than 1 year post-PSE, depending on the preoperative splenic volume, the splenic factors associated with a prolonged increase in platelet counts at 1 year after PSE were retrospectively examined.

Results

In 57 patients with preoperative splenic volumes ≤700 ml, the preoperative splenic volume (P = 0.001), infarcted splenic volume (P < 0.001), and splenic infarction ratio (P = 0.001) showed positive correlations with increments in platelet counts at 1 year post-PSE. In 15 patients with preoperative splenic volumes >700 ml, noninfarcted splenic volume (P = 0.003) and splenic infarction ratio (P = 0.002) showed negative and positive correlations with the increment in platelet counts at 1 year post-PSE, respectively.

Conclusions

In patients with splenic volumes ≤700 ml, the infarcted splenic area significantly affects the prolonged increase in platelet counts post-PSE. In patients with splenic volumes >700 ml, the noninfarcted splenic area is significant.
Literature
1.
go back to reference Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology. 1995;22:1682–8.CrossRefPubMed Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology. 1995;22:1682–8.CrossRefPubMed
2.
go back to reference Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 1993;18:309–14.CrossRefPubMed Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 1993;18:309–14.CrossRefPubMed
3.
go back to reference Mozes MF, Spigos DG, Pollak R, Abejo R, Pavel DG, Tan WS, et al. Partial splenic embolization, an alternative to splenectomy—results of a prospective, randomized study. Surgery. 1984;96:694–702.PubMed Mozes MF, Spigos DG, Pollak R, Abejo R, Pavel DG, Tan WS, et al. Partial splenic embolization, an alternative to splenectomy—results of a prospective, randomized study. Surgery. 1984;96:694–702.PubMed
4.
go back to reference N’Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, et al. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol. 2005;17:179–84.CrossRefPubMed N’Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y, Castera L, et al. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol. 2005;17:179–84.CrossRefPubMed
5.
go back to reference Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Tanaka M, Sakai T, et al. Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology. 1986;33:105–8.PubMed Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Tanaka M, Sakai T, et al. Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology. 1986;33:105–8.PubMed
6.
go back to reference Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 2002;49:1445–8.PubMed Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 2002;49:1445–8.PubMed
7.
go back to reference Yoshida H, Mamada Y, Taniai N, Tajiri T. Partial splenic embolization. Hepatol Res. 2008;38:225–33.CrossRefPubMed Yoshida H, Mamada Y, Taniai N, Tajiri T. Partial splenic embolization. Hepatol Res. 2008;38:225–33.CrossRefPubMed
8.
go back to reference Foruny JR, Blazquez J, Moreno A, Barcena R, Gil-Grande L, Quereda C, et al. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol. 2005;17:1157–64.CrossRefPubMed Foruny JR, Blazquez J, Moreno A, Barcena R, Gil-Grande L, Quereda C, et al. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol. 2005;17:1157–64.CrossRefPubMed
9.
go back to reference Palsson B, Verbaan H. Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2005;17:1153–5.CrossRefPubMed Palsson B, Verbaan H. Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2005;17:1153–5.CrossRefPubMed
10.
go back to reference Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia. Transpl Int. 2006;19:255–7.CrossRefPubMed Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia. Transpl Int. 2006;19:255–7.CrossRefPubMed
11.
go back to reference Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, et al. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol. 2007;22:1638–42.CrossRefPubMed Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, et al. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol. 2007;22:1638–42.CrossRefPubMed
12.
go back to reference Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg. 2008;95:744–50.CrossRefPubMed Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg. 2008;95:744–50.CrossRefPubMed
13.
go back to reference Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lunderquist A, Owman T. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg. 1982;196:518–24.CrossRefPubMed Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lunderquist A, Owman T. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg. 1982;196:518–24.CrossRefPubMed
14.
go back to reference Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.CrossRefPubMed Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.CrossRefPubMed
15.
go back to reference McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.CrossRefPubMed McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.CrossRefPubMed
Metadata
Title
Therapeutic factors considered according to the preoperative splenic volume for a prolonged increase in platelet count after partial splenic embolization for liver cirrhosis
Authors
Hiromitsu Hayashi
Toru Beppu
Kazutoshi Okabe
Toshiro Masuda
Hirohisa Okabe
Takatoshi Ishiko
Hideo Baba
Publication date
01-05-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0185-9

Other articles of this Issue 5/2010

Journal of Gastroenterology 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.